Radiopharmaceutical · Acts on Melanocortin-1 receptor (MC1R) · developed by Perspective Therapeutics
Lead Pb 203-VMT01 is a radioconjugate in which the melanocyte-stimulating hormone receptor-targeting peptide VMT01 carries the radioisotope lead Pb 203. The peptide binds MC1R, a G protein-coupled receptor upregulated on metastatic melanoma cells, allowing those cells to be detected by SPECT/CT imaging. It is studied in recurrent and metastatic melanoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05655312 | Phase 1/2 | Recurrent Melanoma (Skin) | Recruiting | CATX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Melanoma Stage IIIMelanoma Stage IVMetastatic MelanomaRecurrent Melanoma (Skin)
Updated Oct 11, 2026. Something wrong or missing? Report it on the CATX page.
See CATX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CATX catalysts and pipeline →